Silexion Therapeutics Corp. (SLXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Silexion (SLXN)

Silexion Therapeutics Corp (SLXN) is developing advanced RNA-based treatments for solid tumors, leveraging AI for cellular environment analysis and massive research investments. This price chart illustrates an EV/EBITDA of 0.00, with future capitalization expected to rise driven by KRAS mutation therapies for pancreatic cancer. The company currently generates no revenue, meaning its market value depends on the confirmed efficacy of its drug pipeline.

SLXN Silexion Therapeutics: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/17/2026

SLXN (Silexion Therapeutics Corp.): analytical breakdowns and indicator data

Summary company analytics:SLXN (Silexion)
Original product of Silexion Therapeutics

Investors use this indicator to determine the fair value of a business, stripped of the influence of debt load and tax regimes. The metric compares the enterprise value (EV) to operating profit before depreciation and amortization, measuring the efficiency of cash flow generation. For Silexion Therapeutics Corp (SLXN) in the cancer gene therapy development biotech sector, the EV/EBITDA ratio is critical for monitoring overpayment for future potential.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences, Inc CHRS|Corbus Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc.|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Lixte Biotechnology Holdings LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Ltd.)|CANF (Can-Fite BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia)|NuCana - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix, Inc)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Pharma (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)